Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Talaris Therapeutics Inc (TALS)

Talaris Therapeutics Inc (TALS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,160
  • Shares Outstanding, K 41,723
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,830 K
  • 60-Month Beta 1.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.28
Trade TALS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.52
  • Number of Estimates 3
  • High Estimate -0.49
  • Low Estimate -0.54
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -67.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +50.56%
on 12/28/22
1.4099 -4.96%
on 01/26/23
+0.3550 (+36.04%)
since 12/27/22
3-Month
0.8900 +50.56%
on 12/28/22
1.7100 -21.64%
on 11/07/22
-0.2200 (-14.10%)
since 10/27/22
52-Week
0.8900 +50.56%
on 12/28/22
10.5600 -87.31%
on 04/07/22
-7.6600 (-85.11%)
since 01/27/22

Most Recent Stories

More News
Talaris (TALS) Down on Patient Death From Renal Transplant Study

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

CPRX : 15.52 (-2.94%)
AERI : 15.25 (+0.07%)
ACER : 2.36 (-2.48%)
TALS : 1.3400 (-2.19%)
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics to Present at the Jefferies Healthcare Conference

BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update

Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001

Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company...

TALS : 1.3400 (-2.19%)
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results

Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two...

TALS : 1.3400 (-2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe...

See More

Key Turning Points

3rd Resistance Point 1.5052
2nd Resistance Point 1.4562
1st Resistance Point 1.3981
Last Price 1.3400
1st Support Level 1.2910
2nd Support Level 1.2420
3rd Support Level 1.1839

See More

52-Week High 10.5600
Fibonacci 61.8% 6.8661
Fibonacci 50% 5.7250
Fibonacci 38.2% 4.5839
Last Price 1.3400
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar